AstraZeneca PLC (LON:AZN)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 212.96B +10.7% |
| Revenue (ttm) | 46.99B +7.3% |
| Net Income | 8.31B +17.4% |
| EPS | 5.32 +17.3% |
| Shares Out | 1.55B |
| PE Ratio | 25.82 |
| Forward PE | 16.13 |
| Dividend | 2.39 (1.74%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 1,130,726 |
| Open | 13,376 |
| Previous Close | 13,052 |
| Day's Range | 13,348 - 13,820 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 15,779.23 (+14.93%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,779p, which is an increase of 14.93% from the latest price.
News
AstraZeneca Quarterly report: Q3 2026
AstraZeneca has published its Q3 2026 quarterly earnings report on October 30, 2026.
AstraZeneca Slides: Q3 2026
AstraZeneca has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan
AstraZeneca's net profit jumped 23% in the third quarter on booming sales of its cancer drugs, as the British drugmaker unveiled a programme to save $1.5 billion (€1.34bn) a year to invest back into d...
AstraZeneca launches overhaul to cut costs by £1.1bn a year
Anglo-Swedish AstraZeneca employs 100,000 workers globally, of which around 10,000 are based in the UK.
AstraZeneca CFO Aradhana Sarin on Q3 results, oncology portfolio and drug pipeline outlook
Aradhana Sarin, AstraZeneca CFO, joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's oncology portfolio, drug pipeline outlook, and more.
FTSE 100 Modestly Higher; AstraZeneca Rises On Strong Earnings
(RTTNews) - U.K. stock market's benchmark FTSE 100 moved higher Friday morning, supported by strong results from pharma major AstraZeneca and energy giant BP. Weakness in bank and mining stocks limite...
AstraZeneca Q3 Profit Rises; Pipeline Delivers 12 Positive Phase 3 Readouts; Stock Up
(RTTNews) - AstraZeneca PLC (AZN) on Friday reported higher third-quarter profit and revenue, supported by growth across its major therapy areas. The company reaffirmed its full-year revenue and core ...
FTSE 100 set for monthly gains; AstraZeneca up after results
London's FTSE 100 looked on track to log its first monthly gain in three months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.
AstraZeneca reports Q3 core EPS $2.79
Reports Q3 revenue $16.21B, consensus $16B. The company said, ‘In the first nine months we saw strong commercial momentum with total revenue up 7% and Core EPS up 14%, driven…
AstraZeneca backs FY26 core EPS view up low single digits
Backs FY26 revenue view up mid-to-high single digits. The company said, “AstraZeneca (AZN) reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER, based on the average foreign…
AstraZeneca Q3 Profit Rises; Reconfirms FY26 Revenue, Core EPS Guidance At CER
(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) reported that its third quarter profit attributable to owners of the Parent increased to $3.12 billion from $2.53 billion, prior year. Diluted ...
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales
The U.K. drugmaker reported net profit of $3.12 billion for the third quarter, up from $2.535 billion for the same period last year.
AstraZeneca, Mark-Paul Gosselaar partner for ‘Meet Your Mark’ campaign
AstraZeneca (AZN) announced the launch of Meet Your Mark, a new public health campaign featuring actor Mark-Paul Gosselaar. The campaign encourages people to ask about biomarker testing if they or…
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the launch of Meet Your Mark, a new public health campaign featuring actor Mark-Paul Gosselaar. The campaign encourages people to ask abo...
Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research
TORONTO--(BUSINESS WIRE)--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for Can...
Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
Innate Pharma S.A. announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously...
AstraZeneca PLC Announces EU Approval of Enhertu for HER2-Positive Early Breast Cancer Following 53% Risk Reduction in Phase III Trial
AstraZeneca PLC announced that Enhertu has been approved in the European Union as a monotherapy for the adjuvant treatment of adult patients with resected HER2-positive breast cancer who have residual...
AstraZeneca, Daiichi Sankyo's Enhertu Wins First EU Approval In Early Breast Cancer Setting
(RTTNews) - On Tuesday, AstraZeneca (AZN) and Daiichi Sankyo (4568.T) said the European Commission approved Enhertu in the European Union, or EU as a standalone treatment after surgery for adults with...
AstraZeneca Names Onco360 National Speciality Pharmacy Partner For Zegfrovy
(RTTNews) - AstraZeneca (AZN) has selected Onco360 as a national speciality pharmacy partner for Zegfrovy (sunvozertinib), which is indicated for the treatment of adults with locally advanced or metas...
Innate Pharma announces AstraZeneca updated timing for PACIFIC-9 data readout
Innate Pharma (IPHA) announced that AstraZeneca (AZN) has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second…
AstraZeneca announces Enhertu approval in the European Union
Enhertu has been approved in the European Union, or EU, as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive…
AstraZeneca Projects $80 Bln In Total Revenue By 2030, Sustained Growth Beyond
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced that it aims for $80 billion in total revenue by 2030, and sustained growth beyond the year.
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update
Astrazeneca NYSE: AZN highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the...
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAstrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor e...